1544508
USP
吡罗昔康
United States Pharmacopeia (USP) Reference Standard
别名:
2-甲基-4-羟基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-甲酰胺-1,1-二氧化物
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C15H13N3O4S
CAS Number:
分子量:
331.35
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
piroxicam
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O
InChI
1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
InChI key
QYSPLQLAKJAUJT-UHFFFAOYSA-N
基因信息
human ... PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Piroxicam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Piroxicam Capsules
- Piroxicam Compounded Cream
- Piroxicam Compounded Oral Suspension
生化/生理作用
环加氧酶抑制剂。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - STOT RE 2 Oral
靶器官
Gastrointestinal tract
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
D Gerber
Drug intelligence & clinical pharmacy, 21(9), 707-710 (1987-09-01)
During the approximately five years (1981-86) that piroxicam has been available in South Africa, the Medicines Safety Centre has received 31 reports of adverse reactions associated with this drug. Among these are two reactions not previously recorded in the literature
P Pfitzenmeyer et al.
The Journal of rheumatology, 21(8), 1573-1577 (1994-08-01)
We describe 2 patients who developed pulmonary infiltrates while being treated with piroxicam. There was no satisfactory explanation other than drug induced lung disease for their illness. They had no exposure to pneumotoxic drugs or aerocontaminants. Microorganisms were not cultured
R E Lister et al.
European journal of rheumatology and inflammation, 12(4), 6-11 (1993-01-01)
Piroxicam-beta-cyclodextrin is a novel NSAID; it is a supermolecular inclusion complex designed to improve the risk:benefit ratio of piroxicam. In animal studies it has been shown to be as effective as piroxicam as an anti-inflammatory and analgesic agent but with
C R Lee et al.
Drugs, 48(6), 907-929 (1994-12-01)
Piroxicam-beta-cyclodextrin is a complex of the established nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, beta-cyclodextrin. In clinical trials in patients with rheumatic diseases or pain arising from other conditions, it was as effective an analgesic as standard
F Plantema
Acta obstetricia et gynecologica Scandinavica. Supplement, 138, 15-17 (1986-01-01)
In double-blind, crossover studies, piroxicam was compared with naproxen. Piroxicam 40 mg was given once daily for two days, followed by 20 mg once daily and is compared with naproxen 750 mg daily for two days, followed by 500 mg
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持